Welcome to our dedicated page for Alkermes plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc stock.
Alkermes Inc. plc (NASDAQ: ALKS) is a global biopharmaceutical company dedicated to developing innovative medicines for treating central nervous system (CNS) diseases. Headquartered in Dublin, Ireland, Alkermes has a significant presence in the United States with a research and development center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. The company’s mission is to leverage its proprietary technologies to create and commercialize pharmaceutical products that address unmet medical needs in conditions such as schizophrenia, depression, addiction, and multiple sclerosis.
Alkermes’ diversified product portfolio includes notable medications like LYBALVI®, ARISTADA®, and VIVITROL®. These products are pivotal in the treatment of mental health disorders and substance abuse, demonstrating the company's commitment to enhancing patient outcomes. LYBALVI®, a combination of olanzapine and samidorphan, is used for treating schizophrenia and bipolar I disorder. ARISTADA® is an extended-release injectable suspension for schizophrenia, and VIVITROL® is used for alcohol and opioid dependence.
The company's robust clinical pipeline features breakthrough candidates such as ALKS 2680, an investigational orexin 2 receptor agonist targeting narcolepsy. Recent study results announced in early 2024 have shown promising improvements in wakefulness for patients with narcolepsy type 2 and idiopathic hypersomnia, validating the potential of ALKS 2680 to address critical gaps in treatment.
Alkermes has also engaged in significant corporate developments, including the sale of its Athlone, Ireland facility to Novo Nordisk, aimed at increasing operational efficiency. Financially, the company reported total revenues of $1.66 billion for 2023, with a net income of $356 million, emphasizing strong growth and profitability. The company's strategic focus on neuroscience and operational efficiency is expected to drive sustained profitability and innovation in treating CNS disorders.
For more detailed information about Alkermes’ products, clinical trials, and corporate strategies, you can visit their official website at www.alkermes.com.
Alkermes has been recognized in Ragan Communications and PR Daily's 2023 list of Top Places to Work. This accolade highlights the company's commitment to creating a positive work environment and employee satisfaction.
The announcement underscores Alkermes' focus on workplace culture, which may enhance its reputation and attract talent. For those interested in joining the team, job opportunities are available on their careers page.
Alkermes plc (Nasdaq: ALKS) announced the publication of the ENLIGHTEN-Early study results for LYBALVI (olanzapine and samidorphan) in the Journal of Clinical Psychiatry. The phase 3 trial focused on body weight effects in young adults (ages 16-39) with schizophrenia or bipolar I disorder. LYBALVI demonstrated a statistically significant reduction in weight gain compared to olanzapine, with mean weight changes at Week 12 being 4.91% for LYBALVI versus 6.77% for olanzapine (p=0.012). The safety profile was consistent with prior studies. The findings contribute to the understanding of LYBALVI as a treatment option for patients early in their illness.
Alkermes hosted an enlightening discussion featuring Dr. Kevin M. Simon, Boston's Chief Behavioral Health Officer, addressing implicit bias and mental health stigma in minority communities. Dr. Simon highlighted the mental health challenges faced by Dr. Martin Luther King Jr. and emphasized the importance of allyship in promoting diversity and inclusion. Alkermes continues to focus on ending the stigma surrounding mental health issues, aligning with its commitment to innovation in neuroscience and oncology.
With a global presence, Alkermes develops medicines for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, alongside an evolving pipeline for neurodegenerative disorders and cancer.
On March 15, 2023, Alkermes plc (NASDAQ: ALKS) announced its participation in a fireside chat at the Stifel 2023 CNS Days. The event will take place on March 29, 2023, at 9:00 a.m. ET (2:00 p.m. BST). The live webcast can be accessed on the Investors tab of Alkermes' website and will be available for 14 days post-event. Alkermes is a global biopharmaceutical company focused on neuroscience and oncology, offering products for alcohol and opioid dependence, schizophrenia, and bipolar I disorder. For more details, visit www.alkermes.com.
Alkermes reported a revenue of $1.11 billion for 2022, down from $1.17 billion in 2021, with a GAAP loss per share of $0.97. Non-GAAP earnings per share stood at $0.34. The company generated $96 million in net sales from LYBALVI® in its first full year of launch and experienced double-digit growth in sales of VIVITROL® and ARISTADA®. For 2023, Alkermes projects total revenue between $1.13 billion and $1.25 billion and a GAAP net loss between $160 million and $200 million, anticipating continued growth in proprietary products and a planned separation of its oncology business.
Alkermes highlights its organizational culture founded on compassion, scientific integrity, and impactful contributions to society. This commitment is evident in their team dynamics and innovative approaches to healthcare challenges. The company aims to engage stakeholders through various channels, promoting their values and efforts in enhancing public health. The press release encourages viewers to learn more about the company culture via a dedicated video, emphasizing the importance of the human element in their operations.
Alkermes plc (Nasdaq: ALKS) will conduct a conference call and webcast on February 16, 2023, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2022 financial results. The management will also outline financial expectations for 2023 and provide company updates. Interested parties can access the webcast through Alkermes' website. U.S. callers can join by dialing +1 877 407 2988, while international callers can reach +1 201 389 0923. A replay will be available two hours post-event.
Alkermes has released an animation that explores how alcohol dependence impacts the brain, aligning with the conclusion of Dry January. The initiative aims to raise awareness about alcohol-related issues and includes a questionnaire designed to help individuals assess their drinking habits. For those interested, additional multimedia content and ESG storytelling are available through Alkermes' profile on 3blmedia.com. This educational effort reflects Alkermes' commitment to addressing alcohol dependence and supporting individuals seeking help.
FAQ
What is the current stock price of Alkermes plc (ALKS)?
What is the market cap of Alkermes plc (ALKS)?
What does Alkermes Inc. plc specialize in?
What are some key products of Alkermes?
Where is Alkermes headquartered?
What recent achievements has Alkermes announced?
How did Alkermes perform financially in 2023?
What strategic moves has Alkermes made recently?
What is ALKS 2680?
What initiatives support Alkermes' commitment to mental health?
How can I get more information about Alkermes?
What partnerships or collaborations is Alkermes involved in?
